Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab.
Ryan ZubrickyJasmyne McCoyRichard DonkorDavid G MillerNina SonbolianAndrew HeaneyVer BilanoHelene KarcherJoseph M ConeyPublished in: Ophthalmology and therapy (2023)
In this real-world study, most IOI-related AEs occurred early after brolucizumab treatment initiation. With appropriate monitoring and management of IOI-related AEs, vision loss associated with brolucizumab may be limited.